RXL-2TRZ 60mg Peptide | Third-Party Tested | RemedyX Labs
Order RXL-2TRZ 60mg research peptide online from RemedyX Labs. Verified batch COAs confirm purity and identity. Secure checkout, competitive pricing, and fast shipping.
RXL-2TRZ is a synthetic research peptide supplied as a lyophilized powder. It is used in controlled laboratory studies of dual-receptor signaling and metabolic research models. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.
- Price: 129.00 USD
- In stock
- Purity: 99%+
- CAS Number: 2023788-19-2
- Molecular Formula: C225H348N48O68
- Molecular Weight: 4813
- Specification: 60mg/vial
- Contents: Lyophilized Powder
- Appearance: White to Off-White
- Intended Use: Research Only
- SKU: RXL-SKU-0032
Cited Research
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control (SURPASS-5)
The SURPASS-5 trial evaluated the impact of subcutaneous tirzepatide on glycemic control when added to insulin glargine therapy.
PubMed
Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide (SURPASS-1)
The SURPASS-1 study assessed the efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide.
PubMed
Tirzepatide, a Dual GIP/GLP-1 Receptor Co-Agonist for the Treatment of Type 2 Diabetes
This review discusses the mechanism and therapeutic application of tirzepatide as a dual GIP and GLP-1 receptor co-agonist for type 2 diabetes.
PubMed
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
This phase 1 study evaluates the multiple-ascending dose pharmacokinetics of tirzepatide in Japanese participants with type 2 diabetes.
PubMed, 2021
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
This research assesses the application of tirzepatide in treating patients with heart failure with preserved ejection fraction and obesity.
PubMed, 2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
This study evaluates the effectiveness of tirzepatide in patients diagnosed with metabolic dysfunction-associated steatohepatitis and liver fibrosis.
PubMed, 2024
Structural determinants of dual incretin receptor agonism by tirzepatide
Researchers investigated the structural mechanisms by which tirzepatide achieves dual agonist activity at both GIP and GLP-1 receptors.
PubMed, 2022
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
This study evaluated the effects of tirzepatide administration in patients with obesity and obstructive sleep apnea.
PubMed, 2024
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials
A pooled post hoc analysis of clinical trial data examined the association between tirzepatide treatment and reduced albuminuria in patients with type 2 diabetes.
PubMed, 2025
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
This investigation characterized the imbalanced and biased nature of tirzepatide as a dual agonist of GIP and GLP-1 receptors.
PubMed, 2020
Tirzepatide Once Weekly for the Treatment of Obesity
Reports substantial sustained weight reductions over 72 weeks.
PubMed, 2022
Weight loss efficiency and safety of tirzepatide: a systematic review and meta-analysis
Synthesizes dose-related weight loss and adverse-event findings.
PMC, 2023
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Reports greater categorical and mean weight loss with tirzepatide than semaglutide in the trial population.
PubMed, 2025
Tirzepatide for overweight and obesity management
Reviews efficacy, safety, cardiovascular outcomes and remaining evidence gaps.
PubMed, 2025
Tirzepatide as a novel effective and safe strategy for weight loss in patients with obesity
Finds significant reductions in weight-related measures with gastrointestinal adverse events requiring attention.
PubMed, 2024
Tirzepatide: A Systematic Update
Summarizes the early clinical-trial program and mechanism.
PubMed, 2022
Tirzepatide and muscle composition changes in people with obesity
Examines changes in muscle volume and fat infiltration during treatment.
PubMed, 2025
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes
Finds significant weight reduction across included randomized trials.
PubMed, 2025